Provided herein, in part, is a new class of sterically bulky, easily prepared N-heterocyclic carbene (NHC) ligands of Formula I, or a salt, solvate, geometric isomer, or stereoisomer thereof. The ligands are readily synthetically accessible exploiting the cost-effective, modular alkylation of anilines. The NHC ligands of the present disclosure can be used to prepare effective catalysts with transition metals, including the compound of Formula II, or a salt, solvate, geometric isomer, or stereoisomer thereof. In certain embodiments, the transition metal is Pd.

The present invention relates to the field of perfumery. More particularly, it relates to compounds of formula (I) that are able to provide a long-lasting or substantive odor to the environment. Moreover, the present invention relates to a method of imparting a long-lasting odor to environment or to surfaces, such as hard surfaces, fabric, skin or hair. Furthermore, the present invention relates to the use of said compounds in perfumery, as well as the perfuming compositions or perfumed articles comprising the invention’s compounds.

The present invention relates to the field of perfumery. More particularly, it relates to compounds of formula (I) that are able to provide a long-lasting or substantive odor to the environment. Moreover, the present invention relates to a method of imparting a long-lasting odor to environment or to surfaces, such as hard surfaces, fabric, skin or hair. Furthermore, the present invention relates to the use of said compounds in perfumery, as well as the perfuming compositions or perfumed articles comprising the invention’s compounds.

A light-emitting device including an organic layer disposed between a first electrode and a second electrode, the organic layer comprising a fluorescent compound, wherein upon excitation, excitons in a .sup.3n-π* excited state of the fluorescent compound migrate to a .sup.1π-π* excited state of the fluorescent compound by reverse intersystem crossing with a Rate (rISC), and then undergo radiative transition to a ground state to emit light via fluorescence. The fluorescent compound is defined by a ratio of Rate (rISC) to Rate (IC) is 0.5 or greater. An electronic apparatus including the light-emitting device, and the fluorescent compound.

A light-emitting device including an organic layer disposed between a first electrode and a second electrode, the organic layer comprising a fluorescent compound, wherein upon excitation, excitons in a .sup.3n-π* excited state of the fluorescent compound migrate to a .sup.1π-π* excited state of the fluorescent compound by reverse intersystem crossing with a Rate (rISC), and then undergo radiative transition to a ground state to emit light via fluorescence. The fluorescent compound is defined by a ratio of Rate (rISC) to Rate (IC) is 0.5 or greater. An electronic apparatus including the light-emitting device, and the fluorescent compound.

The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.

The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.

Provided herein are therapeutic and/or prophylactic compounds for mitochondrial or oxidative stress diseases such as cancer, amyotropic lateral sclerosis, Creutzfeldt-Jakob disease, Machado-Joseph disease, spinocerebellar ataxia, Huntington disease, Parkinson disease, Alzheimer disease, myocardial infarction, cerebral infarction, diseases related to aging, diabetes, alcoholic liver injury, chronic obstructive pulmonary disease, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), and the like, wherein the compound is represented by formula (1), or reduced forms thereof, or pharmaceutically acceptable salts thereof.

##STR00001##

Provided herein are therapeutic and/or prophylactic compounds for mitochondrial or oxidative stress diseases such as cancer, amyotropic lateral sclerosis, Creutzfeldt-Jakob disease, Machado-Joseph disease, spinocerebellar ataxia, Huntington disease, Parkinson disease, Alzheimer disease, myocardial infarction, cerebral infarction, diseases related to aging, diabetes, alcoholic liver injury, chronic obstructive pulmonary disease, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), and the like, wherein the compound is represented by formula (1), or reduced forms thereof, or pharmaceutically acceptable salts thereof.

##STR00001##

The present invention relates to methods to use cyclohexan-1,2-dione (CHD) groups to attach labels, linkers, and other molecules to a target compound comprising a CHD-reactive group such as a guanidine, amidine, urea, thiourea and the like. Methods of the invention include milder conditions than those previously known for promoting reaction of CHD with CHD-reactive groups, which makes the methods suitable for use with base-sensitive compounds and complex biomolecules. Methods of the invention are especially useful for attaching linking and labeling groups to a peptide that comprises at least one arginine residue, and can also be used to link such peptides to other target molecules such as nucleic acids. The invention also provides CHD-containing conjugation reagents and compositions comprising CHD-containing intermediates, and precursors useful for making CHD-containing compounds that can be used in the methods of the invention.